Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses

Abstract Chronic ketamine abuse is associated with bladder dysfunction and cystitis. However, the effects of ketamine abuse on the urinary proteome profile and the correlations among urinary proteins, urinary ketamine (and metabolites) and clinicopathological features of ketamine-induced bladder dys...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jo-Chuan Liu, Yi-Ting Chen, Ya-Ju Hsieh, Chia-Chun Wu, Ming-Chyi Huang, Yu-Chao Hsu, Chun-Te Wu, Chih-Ken Chen, Srinivas Dash, Jau-Song Yu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/757bb9f16aab458b9821a477bd5e1bc6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:757bb9f16aab458b9821a477bd5e1bc6
record_format	dspace
spelling	oai:doaj.org-article:757bb9f16aab458b9821a477bd5e1bc62021-12-02T16:51:39ZAssociation of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses10.1038/s41598-021-89089-42045-2322https://doaj.org/article/757bb9f16aab458b9821a477bd5e1bc62021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89089-4https://doaj.org/toc/2045-2322Abstract Chronic ketamine abuse is associated with bladder dysfunction and cystitis. However, the effects of ketamine abuse on the urinary proteome profile and the correlations among urinary proteins, urinary ketamine (and metabolites) and clinicopathological features of ketamine-induced bladder dysfunction remain to be established. Here, we recruited 56 ketamine abusers (KA) and 40 age-matched healthy controls (HC) and applied the iTRAQ-based proteomics approach to unravel quantitative changes in the urine proteome profile between the two groups. Many of the differentially regulated proteins are involved in the complement and coagulation cascades and/or fibrotic disease. Among them, a significant increase in APOA1 levels in KA relative to control samples (392.1 ± 59.9 ng/ml vs. 13.7 ± 32.6 ng/ml, p < 0.0001) was detected via ELISA. Moreover, urinary ketamine, norketamine and dehydronorketamine contents (measured via LC-SRM-MS) were found to be positively correlated with overactive bladder syndrome score (OABSS) and APOA1 levels with urinary RBC, WBC, OABSS and numeric pain rating scale in KA. Collectively, our results may aid in developing new molecular tool(s) for management of ketamine-induced bladder dysfunction. Moreover, information regarding the differentially regulated proteins in urine of KA provides valuable clues to establish the molecular mechanisms underlying ketamine-induced cystitis.Jo-Chuan LiuYi-Ting ChenYa-Ju HsiehChia-Chun WuMing-Chyi HuangYu-Chao HsuChun-Te WuChih-Ken ChenSrinivas DashJau-Song YuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jo-Chuan Liu Yi-Ting Chen Ya-Ju Hsieh Chia-Chun Wu Ming-Chyi Huang Yu-Chao Hsu Chun-Te Wu Chih-Ken Chen Srinivas Dash Jau-Song Yu Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses
description	Abstract Chronic ketamine abuse is associated with bladder dysfunction and cystitis. However, the effects of ketamine abuse on the urinary proteome profile and the correlations among urinary proteins, urinary ketamine (and metabolites) and clinicopathological features of ketamine-induced bladder dysfunction remain to be established. Here, we recruited 56 ketamine abusers (KA) and 40 age-matched healthy controls (HC) and applied the iTRAQ-based proteomics approach to unravel quantitative changes in the urine proteome profile between the two groups. Many of the differentially regulated proteins are involved in the complement and coagulation cascades and/or fibrotic disease. Among them, a significant increase in APOA1 levels in KA relative to control samples (392.1 ± 59.9 ng/ml vs. 13.7 ± 32.6 ng/ml, p < 0.0001) was detected via ELISA. Moreover, urinary ketamine, norketamine and dehydronorketamine contents (measured via LC-SRM-MS) were found to be positively correlated with overactive bladder syndrome score (OABSS) and APOA1 levels with urinary RBC, WBC, OABSS and numeric pain rating scale in KA. Collectively, our results may aid in developing new molecular tool(s) for management of ketamine-induced bladder dysfunction. Moreover, information regarding the differentially regulated proteins in urine of KA provides valuable clues to establish the molecular mechanisms underlying ketamine-induced cystitis.
format	article
author	Jo-Chuan Liu Yi-Ting Chen Ya-Ju Hsieh Chia-Chun Wu Ming-Chyi Huang Yu-Chao Hsu Chun-Te Wu Chih-Ken Chen Srinivas Dash Jau-Song Yu
author_facet	Jo-Chuan Liu Yi-Ting Chen Ya-Ju Hsieh Chia-Chun Wu Ming-Chyi Huang Yu-Chao Hsu Chun-Te Wu Chih-Ken Chen Srinivas Dash Jau-Song Yu
author_sort	Jo-Chuan Liu
title	Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses
title_short	Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses
title_full	Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses
title_fullStr	Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses
title_full_unstemmed	Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses
title_sort	association of urinary ketamine and apoa1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/757bb9f16aab458b9821a477bd5e1bc6
work_keys_str_mv	AT jochuanliu associationofurinaryketamineandapoa1levelswithbladderdysfunctioninketamineabusersrevealedviaproteomicsandtargetedmetaboliteanalyses AT yitingchen associationofurinaryketamineandapoa1levelswithbladderdysfunctioninketamineabusersrevealedviaproteomicsandtargetedmetaboliteanalyses AT yajuhsieh associationofurinaryketamineandapoa1levelswithbladderdysfunctioninketamineabusersrevealedviaproteomicsandtargetedmetaboliteanalyses AT chiachunwu associationofurinaryketamineandapoa1levelswithbladderdysfunctioninketamineabusersrevealedviaproteomicsandtargetedmetaboliteanalyses AT mingchyihuang associationofurinaryketamineandapoa1levelswithbladderdysfunctioninketamineabusersrevealedviaproteomicsandtargetedmetaboliteanalyses AT yuchaohsu associationofurinaryketamineandapoa1levelswithbladderdysfunctioninketamineabusersrevealedviaproteomicsandtargetedmetaboliteanalyses AT chuntewu associationofurinaryketamineandapoa1levelswithbladderdysfunctioninketamineabusersrevealedviaproteomicsandtargetedmetaboliteanalyses AT chihkenchen associationofurinaryketamineandapoa1levelswithbladderdysfunctioninketamineabusersrevealedviaproteomicsandtargetedmetaboliteanalyses AT srinivasdash associationofurinaryketamineandapoa1levelswithbladderdysfunctioninketamineabusersrevealedviaproteomicsandtargetedmetaboliteanalyses AT jausongyu associationofurinaryketamineandapoa1levelswithbladderdysfunctioninketamineabusersrevealedviaproteomicsandtargetedmetaboliteanalyses
_version_	1718382925497499648

Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses

Ejemplares similares